Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

5.460 +0.090 (+1.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Immuneering Announces Closing of $25 Million Private Placement
From Immuneering Corporation
Via GlobeNewswire
Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips
Via Stocktwits
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
From Immuneering Corporation
Via GlobeNewswire
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Top movers analysis in the middle of the day on 2025-08-21: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Immuneering Announces $25 Million Private Placement
From Immuneering Corporation
Via GlobeNewswire
Immuneering Posts Narrower Loss in Q2
Via The Motley Fool
Topics Intellectual Property
Curious about the stocks that are showing activity after the closing bell on Wednesday?
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
From Immuneering Corporation
Via GlobeNewswire
Unusual volume stocks are being observed in Wednesday's session.
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
These stocks have an unusual volume in today's session
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Top movers in Wednesday's after hours session
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Which stocks are experiencing notable movement on Wednesday?
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Here are the top movers in Wednesday's session.
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally
The company plans to launch a pivotal trial in 2026 and expects additional clinical data and regulatory feedback by the end of 2025. 
Via Stocktwits
These stocks are moving in today's session
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Corporation Announces Grant of Inducement Award
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback